Enanta's Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is one of the best hot stocks to invest in. On September 29, Enanta Pharmaceuticals reported positive topline results from its Phase 2b study/RSVHR of zelicapavir. Zelicapavir is a novel N-protein inhibitor with Fast Track designation from the FDA, being developed as a once-daily oral treatment for acute Respiratory Syncytial Virus/RSV infection in high-risk adult outpatients.

The study was a randomized, double-blind, placebo-controlled, proof-of-concept trial designed to inform the design of a Phase 3 study, including endpoints and populations, by assessing the antiviral treatment effect on symptoms using the RiiQ (Respiratory Infection Intensity and Impact Questionnaire) patient-reported outcome tool.

Zelicapavir is a lead N-protein inhibitor that targets the virus’s replication machinery, showing a high barrier to resistance in vitro and maintaining antiviral potency across all clinical isolates tested. It is differentiated from RSV fusion inhibitors. The drug has shown a consistent safety profile in 600+ people exposed to date. RSV is a common respiratory virus that poses an increased risk of severe illness, hospitalization, and death for older adults and those with underlying conditions like COPD, CHF, or asthma.

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is a biotechnology company that discovers and develops small-molecule drugs for the treatment of viral infections and liver diseases.

While we acknowledge the potential of ENTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.